Skip to main content

Advertisement

SpringerLink
Log in

A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

We undertook this phase I study to investigate the feasibility of the combination of temozolomide (TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in patients with relapsed high-grade gliomas. Eligible patients were enrolled in this dose escalation study of LP. TMZ was administered at a fixed dose of 200 mg/m2 d1–d5 every 28 days. Starting dose of LP was set at 1,000 mg daily continuously, escalated by 250 mg in cohorts of minimum three patients. Translational research investigations were also undertaken in available biopsy material. Between January 2009 and December 2010, 16 patients were entered into the study at three LP levels: 1,000 mg sid (11 patients), 1,250 mg sid (4 patients) and 1,500 mg sid (1 patient). A total of 55 cycles had been delivered. Fourteen patients had stopped treatment because of disease progression, and two because of toxicity. Three patients received 10, 11 and 17 cycles of treatment. Dose-limiting hematological toxicity was observed in 2 patients at the second LP dose level of 1,250 mg sid. MTD was defined at LP 1,000 mg sid. Median progression-free survival (PFS) and survival were 2.4 and 5.9 months, respectively. EGFR amplification and EGFRvIII expression were not related to PFS. Combination of TMZ and LP is feasible with manageable toxicity. The activity of this combination in patients with recurrent glioblastoma multiforme is further investigated in a recently initiated phase II trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL (2008) Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci USA 105:16707–16712

    Article  PubMed  CAS  Google Scholar 

  2. Bai RY, Staedtke V, Riggins GJ (2011) Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med 17:301–312

    Article  PubMed  CAS  Google Scholar 

  3. Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, Luyken C, Sabel M, Zerrouqi A, Wasner M, Van Meir E, Tolnay M, Reifenberger G, Merlo A (2007) Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE 2:e576

    Article  PubMed  Google Scholar 

  4. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318–325

    Article  PubMed  CAS  Google Scholar 

  5. Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L, Sawaya R, Diao L, Baggerly K, Cavenee WK, Furnari FB, Bogler O (2011) Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of DeltaEGFR. J Proteome Res 10:1343–1352

    Article  PubMed  CAS  Google Scholar 

  6. Custodio A, Calles A, Perez-Segura P (2010) Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. Clin Transl Oncol (Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico) 12:310–314

    Article  CAS  Google Scholar 

  7. Friedman HS, Bigner DD (2005) Glioblastoma multiforme and the epidermal growth factor receptor. New Eng J Med 353:1997–1999

    Article  PubMed  CAS  Google Scholar 

  8. Gadji M, Crous AM, Fortin D, Krcek J, Torchia M, Mai S, Drouin R, Klonisch T (2009) EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Eur J Pharmacol 625:23–30

    Article  PubMed  CAS  Google Scholar 

  9. Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M, Schroth W (2010) Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem 56:1845–1853

    Article  PubMed  CAS  Google Scholar 

  10. Huncharek M, Kupelnick B (2000) Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 12:107–112

    PubMed  CAS  Google Scholar 

  11. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J (1992) Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51:84–90

    Article  PubMed  CAS  Google Scholar 

  12. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD (1992) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66:373–385

    Article  PubMed  CAS  Google Scholar 

  13. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, Wesseling P (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87:1055–1065

    Article  PubMed  CAS  Google Scholar 

  14. Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K, von Kummer R, Schackert G, Krex D (2012) IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol 108:403–410

    Article  PubMed  CAS  Google Scholar 

  15. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro-oncology 12:289–296

    Article  PubMed  CAS  Google Scholar 

  16. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New Eng J Med 353:2012–2024

    Article  PubMed  CAS  Google Scholar 

  17. Mrugala MM, Chamberlain MC (2008) Mechanisms of disease: temozolomide and glioblastoma–look to the future. Nat Clin Pract Oncol 5:476–486

    Article  PubMed  CAS  Google Scholar 

  18. Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177–183

    Article  PubMed  CAS  Google Scholar 

  19. Omuro AM (2008) What is the relevance of determining EGFR-variant-III status in glioblastomas? Nat Clin Pract Oncol 5:188–189

    Article  PubMed  Google Scholar 

  20. Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH (2012) Lapatinib for advanced or metastatic breast cancer. Oncologist 17:536–542

    Article  PubMed  CAS  Google Scholar 

  21. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

    Article  PubMed  CAS  Google Scholar 

  22. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neurooncology 12:95–103

    CAS  Google Scholar 

  23. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (Official Journal of the American Society of Clinical Oncology) 22:133–142

    Article  CAS  Google Scholar 

  24. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120:567–584

    Article  PubMed  CAS  Google Scholar 

  25. Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, O’Neill B, Faul C (2012) A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Br J Radiol 1017:729–733

    Article  Google Scholar 

  26. Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res (An official journal of the American Association for Cancer Research) 12:5268–5272

    Article  CAS  Google Scholar 

  27. Schlegel J, Stumm G, Brandle K, Merdes A, Mechtersheimer G, Hynes NE, Kiessling M (1994) Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 22:201–207

    Article  PubMed  CAS  Google Scholar 

  28. Specenier P (2012) Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther 12:9–18

    Article  PubMed  CAS  Google Scholar 

  29. Stockhammer F, Misch M, Koch A, Czabanka M, Plotkin M, Blechschmidt C, Tuettenberg J, Vajkoczy P (2010) Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 100:407–415

    Article  PubMed  CAS  Google Scholar 

  30. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Eng J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  31. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E (2010) A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65:353–361

    Article  PubMed  CAS  Google Scholar 

  32. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol (Official Journal of the American Society of Clinical Oncology) 27:1268–1274

    Article  Google Scholar 

  33. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110

    Article  PubMed  CAS  Google Scholar 

  34. Weller M, Stupp R, Hegi M, Wick W (2012) Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J 18:40–44

    Article  PubMed  CAS  Google Scholar 

  35. Weller M, Wick W, von Deimling A (2011) Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia 59:1200–1204

    Article  PubMed  Google Scholar 

  36. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972

    Article  PubMed  Google Scholar 

  37. Worm K, Dabbagh P, Schwechheimer K (1999) Reverse transcriptase polymerase chain reaction as a reliable method to detect epidermal growth factor receptor exon 2–7 gene deletion in human glioblastomas. Hum Pathol 30:222–227

    Article  PubMed  CAS  Google Scholar 

  38. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Authors would like to thank Dr. Anna Kalogera-Fountzila, Consultant Radiologist, Ass. Professor of Radiology, Radiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki School of Medicine, for the independent review of images and her extremely helpful assistance. Authors would also like to thank Anastasia Eleftheraki, Statistician, Hellenic Cooperative Oncology Group, Athens, Greece.

Conflicts of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, “Papageorgiou” General Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

    Vasilios Karavasilis, Sofia Lambaki & George Fountzilas

  2. Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

    Vassiliki Kotoula

  3. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

    Vassiliki Kotoula, Despina Televantou, Sofia Chrisafi & Mattheos Bobos

  4. Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece

    George Pentheroudakis

Authors
  1. Vasilios Karavasilis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vassiliki Kotoula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George Pentheroudakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Despina Televantou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sofia Lambaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sofia Chrisafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mattheos Bobos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. George Fountzilas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasilios Karavasilis.

Appendix

Appendix

See Table 4.

Table 4 Frequency table of adverse events (AEs)
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karavasilis, V., Kotoula, V., Pentheroudakis, G. et al. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. J Neurol 260, 1469–1480 (2013). https://doi.org/10.1007/s00415-012-6812-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-012-6812-z

Keywords

Search

Navigation